anti-IL-33, mAb (IL33068A)
1: Human IL-33 (His-tagged).
2: Human IL-33 (FLAG®-tagged).
3: Mouse IL-33 (FLAG®-tagged).
4: Other protein (His-tagged) (negative control).
|Synonyms||Interleukin-33; IL-1F11; NF-HEV|
|Product Type||Monoclonal Antibody|
|Immunogen/Antigen||Recombinant human IL-33.|
ELISA: (direct or indirect: 1:2'000-1:5'000)
Note: Tested on recombinant proteins and/or target-protein transfected cell lines in ELISA, Western Blot and/or FACS.
Recognizes human IL-33. Weakly cross-reacts with mouse IL-33.
|Purity Detail||Protein G-affinity purified.|
|Formulation||Liquid. 0.2μm-filtered solution in PBS, pH 7.4. Contains no preservatives.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
|Use/Stability||Stable for at least 1 year after receipt when stored at -20°C.|
|Product Specification Sheet|
Interleukin-33 (IL-33; HF-NEV; IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released on cell lysis. The 30kDa human IL33 is converted by CASP1 to a 18kDa protein. IL33 binds to and signals through ST2 (IL1R1) and its stimulation recruits MYD88, IRAK, IRAK4, and TRAF6, followed by phosphorylation of ERK1(MAPK3)/ERK2(MAPK1), p38(MAPK14), and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells, and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases, and sepsis.